Watson Pharmaceuticals Inc is on track to announce a M&A deal to buy Actavis for around $6 billion by the end of April, creating one of the world’s biggest producers of generic drugs, sources familiar with the matter said on Wednesday.
While negotiations are complex, there are no major hurdles in sight that would stop the two sides from reaching M&A agreement, two people briefed on the situation said.
Reuters first reported on March 21 that Watson was close to buying Actavis, an unlisted Swiss-based firm, in a potential 5.0-5.5 billion euros ($6.5-7.2 billion) deal. Since then some sources have said the price may be nearer 4.5 billion euros.
Read the full article at Reuters
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity